The lab's models are pre-clinical from the bench to the bedside for diseases such as asthma, cystic fibrosis, bronchopulmonary disease and allergy/anaphylaxis. The Bonfield team are innovative in ...

Vaginal atrophy is inflammation, dryness, and thinning of the vaginal walls. Natural remedies include using lubricants, exercising, and staying sexually active. Vaginal atrophy is better known as ...

William A. Jones, M.D., F.R.C.P.(C) Familial multilocular cystic disease of the jaws, the title of this paper, is a provisional name, given to describe an unusual condition occurring in three children ...

Spinal muscular atrophy (SMA) is a disorder affecting the motor neurons—nerve cells that control voluntary muscle movement. These cells are located in the spinal cord. Because the muscles cannot ...

22. Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation ...

It occurs when tissue similar to the lining of the uterus, called the endometrium, grows outside the uterine cavity. These abnormal growths, known as endometriotic lesions, can attach to various ...

The Mayo Clinic and Exact Sciences are developing an easy, noninvasive test to detect endometrial cancer in women with abnormal vaginal bleeding. It analyzes vaginal fluid collected on tampons for ...

The financing will help Character bring its two most advanced programs into clinical testing. One, dubbed CTX114, is being tested in geographic atrophy, a common eye condition and an advanced stage of ...

22, 2025. Scholar Rock announced today that the FDA granted priority review for a biologics license application (BLA) for apitegromab, a treatment for spinal muscular atrophy (SMA), according to a ...

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several companies—including Novartis, Scholar Rock and Biogen—progressing novel candidates through ...